Carbamazepine: Seizure Medication Side Effects & Dosage


Generic drug: carbamazepine

Brand name: Carnexiv

What is Carnexiv (carbamazepine), and how does it work?

Carnexiv (carbamazepine) injection is an anticonvulsant indicated as replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following seizure types:

  • partial seizures with complex symptomatology, generalized tonic-clonic seizures, mixed seizure patterns which include the above, or other partial or generalized seizures.

What are the side effects of Carnexiv?

Common side effects of Carnexiv include:

WARNING

SERIOUS DERMATOLOGIC REACTIONS and APLASTIC ANEMIA AND AGRANULOCYTOSIS

Serious Dermatologic Reactions and HLA-B*1502 Allele

  • Serious and sometimes fatal dermatologic reactions, including toxic epidermal
    necrolysis (TEN) and Stevens-Johnson syndrome (SJS), have occurred in patients
    treated with carbamazepine.
  • There is a strong association between the risk of
    developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant
    of the HLA-B gene that is found almost exclusively in patients with Asian
    ancestry.
  • Avoid use of Carnexiv in patients testing positive for the allele
    unless the benefit clearly outweighs the risk. Discontinue Carnexiv if you
    suspect that the patient is having a serious dermatologic reaction.

Aplastic Anemia and Agranulocytosis

  • Aplastic anemia and agranulocytosis can occur during treatment with
    Carnexiv. Obtain a complete blood count (CBC) before beginning treatment with
    Carnexiv, and monitor CBC periodically.
  • Consider discontinuing Carnexiv if significant bone marrow depression develops.

What is the dosage for Carnexiv?

Dosage Information

  • Carnexiv is a replacement therapy for oral carbamazepine. Carbamazepine treatment should generally be initiated with an oral carbamazepine formulation.
  • The total daily dose of Carnexiv is 70% of the total daily oral carbamazepine dose from which patients are being switched (see Table 1). The total daily dose of
    Carnexiv should be equally divided in four 30-minute infusions, separated by 6 hours.
  • Patients should be switched back to oral carbamazepine administration at their previous total daily oral dose and frequency of administration as soon as clinically appropriate. The use of
    Carnexiv for periods of more than 7 days has not been studied.

Table 1: Determination of Total Daily Dose for Carnexiv Infusion

Total Daily Oral Carbamazepine Dose (mg/day)
Corresponding Total Daily Dose of
Carnexiv (mg/day)
Dose of Carnexiv to be administered every 6 hours (mg)

400
280
70

600
420
105

800
560
140

1,000
700
175

1,200
840
210

1,400
980
245

1,600
1,120
280

What drugs interact with Carnexiv?

Effects Of Carnexiv On Other Drugs

  • Carbamazepine is a potent inducer of hepatic CYP1A2, 2B6, 2C9/19 and 3A4 and may reduce plasma concentrations of concomitant medications mainly metabolized by CYP1A2, 2B6, 2C9/19, and 3A4 through induction of their metabolism (see Tables 5 and 6).

Table 5: Effects of Carbamazepine on Other Drugs

Concomitant Drug Name
Effect of Carbamazepine on Other Drugs
Clinical Recommendation

Boceprevir
Decrease in boceprevir levels
Coadministration of carbamazepine with boceprevir is contraindicated

Acetaminophen, albendazole, alprazolam, aprepitant, buprenorphone, bupropion, citalopram, clonazepam, clozapine, corticosteroids (e.g., prednisolone, dexamethasone), cyclosporine, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, eslicarbazepine, ethosuximide, everolimus, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, mianserin, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, paliperidone, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, sertraline, sirolimus, tadalafil, theophylline, tiagabine, topiramate, tramadol, trazodone, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide
Decrease in concomitant drug levels
Monitor the concentration and consider a dosage adjustment of the concomitant drug(s)

Cyclophosphamide
Increase in cyclophosphamide levels (potential for increased toxicity)
Monitor for signs of increased cyclophosphamide toxicity

Aripiprazole
Decrease in aripiprazole levels
When carbamazepine is added to aripiprazole, the aripiprazole dose should be doubled; additional dose increases should be based on clinical evaluation; when carbamazepine is withdrawn from the combination therapy, the aripiprazole dose should be reduced

Tacrolimus
Decrease in tacrolimus levels
Monitor tacrolimus blood concentrations and make appropriate dosage adjustments

Temsirolimus
Decrease in temsirolimus levels
The use of concomitant strong CYP3A4 inducers such as carbamazepine should be avoided with temsirolimus; if carbamazepine must be coadministered with temsirolimus, consider adjusting the dosage of temsirolimus

Lapatinib
Decrease in lapatinib levels
The use of carbamazepine with lapatinib should generally be avoided; dosage adjustment should be considered if lapatinib is coadministered with carbamazepine; if carbamazepine is started in a patient already taking lapatinib, the dose of lapatinib should be gradually titrated up; if carbamazepine is discontinued, the lapatinib dose should be reduced

Nefazodone
Decrease in nefazodone levels
Coadministration of carbamazepine with nefazodone is contraindicated

Valproate
Decrease in valproate levels
Monitor valproate concentrations when carbamazepine is introduced or withdrawn in patients using valproic acid

Table 6: Effects of Carbamazepine on Other Drugs (Continued)

Concomitant Drug Name
Effect of Carbamazepine on Other Drugs
Clinical Recommendation

Lithium
May increase the risk of neurotoxic side effects
Use with intensive monitoring

Isoniazid
May increase isoniazid-induced hepatotoxicity

Diuretics (e.g., hydrochlorothiazide, furosemide)
May lead to symptomatic hyponatremia

Hormonal contraceptives (e.g., oral and levonorgestrel subdermal implant contraceptives)
May render the contraceptives less effective because the plasma concentrations of the hormones may be decreased; breakthrough bleeding and unintended pregnancies have been reported
Consider alternative or back-up methods of contraception

Neuromuscular blocking agents (e.g., pancuronium, vecuronium, rocuronium, and cisatracurium)
Resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents
Closely monitor patients for more rapid recovery from neuromuscular blockade than expected; infusion rate may need to be higher

Direct acting oral anticoagulants (e.g., rivaroxaban, apixaban, dabigatran, and edoxaban)
Decreased plasma concentrations of these anticoagulants that may be insufficient to achieve the intended therapeutic effect
Coadministration with carbamazepine should generally be avoided

Delavirdine or other non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Decrease in delavirdine or NNRTI levels
Contraindicated with carbamazepine

Effects Of Other Drugs On Carnexiv

  • CYP3A4 inhibitors inhibit Carnexiv metabolism and can thus increase plasma carbamazepine levels.
  • CYP3A4 inducers can increase the rate of Carnexiv metabolism and thus decrease carbamazepine levels (see Table 7).

Table 7: Effects of Other Drugs on Carbamazepine

Concomitant Drug Name
Effect of Concomitant Drug on Carbamazepine
Clinical Recommendation

Aprepitant, cimetidine, ciprofloxacin, danazol, diltiazem, delavirdine, macrolides, erythromycin, troleandomycin, clarithromycin, fluoxetine, fluvoxamine, trazodone, olanzapine, loratadine, terfenadine, omeprazole, oxybutynin, dantrolene, isoniazid, niacinamide, nicotinamide, ibuprofen, propoxyphene, azoles (e.g., ketaconazole, itraconazole, fluconazole, voriconazole), acetazolamide, verapamil, ticlopidine, grapefruit juice, protease inhibitors
Increase in carbamazepine level (by CYP3A4 inhibition)
Closely monitor carbamazepine levels; dosage adjustment may be required

Cisplatin, doxorubicin HCl, felbamate, fosphenytoin, rifampin, phenobarbital, phenytoin, primidone, methsuximide, theophylline, aminophylline
Decrease in carbamazepine level (by CYP3A4 induction)

Loxapine, quetiapine and valproic acid
Decrease in carbamazepine level and increase in metabolite (carbamazepine-10,11-epoxide) levels (both by inhibition of human microsomal epoxide hydrolase)
Closely monitor carbamazepine levels; dosage adjustment may be required

Pharmacodynamic Drug Interactions

Monoamine Oxidase Inhibitors
  • Concomitant treatment with Carnexiv is contraindicated during use of an MAOI or within 14 days after discontinuing an MAOI. Concomitant use can cause serotonin syndrome.

Is Carnexiv safe to use while pregnant or breastfeeding?

  • Pregnancy registry and epidemiological data indicate that carbamazepine can cause fetal harm when administered to a pregnant woman.
  • Patients should be encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information regarding the effects of in utero exposure to
    Carnexiv. To enroll, patients can call the toll-free number 1-888-233-2334. Information about the North American Antiepileptic Drug Pregnancy Registry can be found at http://www.aedpregnancyregistry.org
  • Carbamazepine and its epoxide metabolite are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants exposed to
    Carnexiv, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Check Also

강남 셔츠룸 서울부장

강남 셔츠룸 매정한 나라에요 ㅋㅋㅋ 신규오픈 매장으로 설치 물품들이 많습니다. 역시 시부야 아니랄까봐 우리 나라 정서가 두 들겨야 흥이 더 나는듯 합니다. 아직 소버일때 우리 여자 예쁘니 직원들이랑 사진찍고 놀기  5~2배 정도 들었던것같아요 일환이었던 월성 원전 1호기 조기폐쇄에 대한 감사는 수위 조절이 실패해서 포기 햇엇드랫죠;; 대량 매출 가능한 입지라 확신합니다. 게임센터 규모도 장난 아니더라구요 차량…

Leave a Reply